ES2279632T3 - Modulacion antisentido de la expresion de integrina alfa 4. - Google Patents

Modulacion antisentido de la expresion de integrina alfa 4. Download PDF

Info

Publication number
ES2279632T3
ES2279632T3 ES99942290T ES99942290T ES2279632T3 ES 2279632 T3 ES2279632 T3 ES 2279632T3 ES 99942290 T ES99942290 T ES 99942290T ES 99942290 T ES99942290 T ES 99942290T ES 2279632 T3 ES2279632 T3 ES 2279632T3
Authority
ES
Spain
Prior art keywords
baselineskip
cells
dddseqskip
hskip
hfill
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99942290T
Other languages
English (en)
Spanish (es)
Inventor
C. Frank Bennett
Thomas P. Condon
Lex M. Cowsert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2279632T3 publication Critical patent/ES2279632T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
ES99942290T 1998-10-05 1999-08-19 Modulacion antisentido de la expresion de integrina alfa 4. Expired - Lifetime ES2279632T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US166203 1993-12-13
US09/166,203 US5968826A (en) 1998-10-05 1998-10-05 Antisense inhibition of integrin α4 expression

Publications (1)

Publication Number Publication Date
ES2279632T3 true ES2279632T3 (es) 2007-08-16

Family

ID=22602243

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99942290T Expired - Lifetime ES2279632T3 (es) 1998-10-05 1999-08-19 Modulacion antisentido de la expresion de integrina alfa 4.

Country Status (10)

Country Link
US (2) US5968826A (OSRAM)
EP (1) EP1123414B1 (OSRAM)
JP (2) JP3834204B2 (OSRAM)
AT (1) ATE352639T1 (OSRAM)
AU (1) AU759938B2 (OSRAM)
CA (1) CA2345209C (OSRAM)
DE (1) DE69934998T2 (OSRAM)
DK (1) DK1123414T3 (OSRAM)
ES (1) ES2279632T3 (OSRAM)
WO (1) WO2000020635A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515513A (ja) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド 核酸の肺送達のための組成物および方法
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
DE19860642A1 (de) * 1998-12-29 2000-07-06 Deutsches Krebsforsch Antisense-Oligonukleotid zur Hemmung der Expression des Adhäsionsmoleküls very late antigen 4 (VLA-4) in menschlichen Zellen
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
WO2004021978A2 (en) * 2002-08-19 2004-03-18 Pharmacia Corporation Antisense modulation of endothelial specific molecule 1 expression
AU2004278748B2 (en) * 2003-09-29 2008-09-11 The Regents Of The University Of California Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
JP2008516991A (ja) * 2004-10-20 2008-05-22 アンチセンス セラピューティクス リミテッド インテグリンα４発現のアンチセンス調節
ES2392544T3 (es) * 2005-06-07 2012-12-11 Yale University Métodos de tratamiento del cáncer y otras enfermedades o estados patológicos usando LFMAU y LDT
EP2656850B1 (en) * 2007-10-05 2016-07-27 InDex Pharmaceuticals AB Oligonucleotides for the treatment or alleviation of edema
ES2532404T3 (es) 2008-06-23 2015-03-26 Antisense Therapeutics Ltd Métodos para tratar la esclerosis múltiple usando oligonucleótidos antisentido
AU2011301712C1 (en) * 2010-09-17 2017-01-05 Antisense Therapeutics Ltd Method for reducing the number of certain circulating leukocytes in a human subject
WO2014193625A1 (en) * 2013-05-30 2014-12-04 R-Pharm Overseas, Inc. Fully human antibodies against human receptor integrin alpha-4
EP3294889B1 (en) * 2015-05-11 2021-01-06 Murdoch University Multiple sclerosis treatment
WO2017075670A1 (en) * 2015-11-05 2017-05-11 Children's Hospital Los Angeles "mobilizing leukemia cells"
WO2018174140A1 (ja) * 2017-03-23 2018-09-27 ナパジェン ファーマ，インコーポレテッド 癌細胞の接着活性阻害剤
WO2023039643A1 (en) * 2021-09-20 2023-03-23 Antisense Therapeutics Ltd Methods and kits therefor
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
CN114887034B (zh) * 2022-07-14 2022-10-28 中山莱博瑞辰生物医药有限公司 LLP2A-Ale在制备用于治疗和/或预防外周血淋巴细胞减少症的药物中的用途
JP2025528873A (ja) * 2022-08-16 2025-09-02 ペルシュロン・セラピューティクス・リミテッド Ｃｏｖｉｄ１９の神経学的急性後後遺症（ｎｐａｓｃ）の診断及び治療におけるバイオマーカー及びその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression

Also Published As

Publication number Publication date
EP1123414A4 (en) 2003-10-01
DE69934998T2 (de) 2007-12-06
US6258790B1 (en) 2001-07-10
JP2006141402A (ja) 2006-06-08
DE69934998D1 (de) 2007-03-15
DK1123414T3 (da) 2007-04-10
AU5570399A (en) 2000-04-26
JP4168285B2 (ja) 2008-10-22
AU759938B2 (en) 2003-05-01
EP1123414A1 (en) 2001-08-16
CA2345209C (en) 2014-04-22
ATE352639T1 (de) 2007-02-15
US5968826A (en) 1999-10-19
CA2345209A1 (en) 2000-04-13
EP1123414B1 (en) 2007-01-24
JP2002526555A (ja) 2002-08-20
WO2000020635A1 (en) 2000-04-13
JP3834204B2 (ja) 2006-10-18

Similar Documents

Publication Publication Date Title
ES2279632T3 (es) Modulacion antisentido de la expresion de integrina alfa 4.
ES2307583T3 (es) Inhibicion antisentido de expresion ptpib.
ES2332296T3 (es) Modulacion antisentido de la expresion de survivina.
US6444464B1 (en) Antisense modulation of E2F transcription factor 2 expression
JP3998089B2 (ja) 新規抗アポトーシスｂｃｌ−２−関連タンパク質のアンチセンスモジュレーション
US8093224B2 (en) Antisense modulation of C-reactive protein expression
US20020147165A1 (en) Antisense modulation of calreticulin expression
JP2002526125A (ja) 腫瘍壊死因子−α（ＴＮＦ−α）発現のアンチセンス・オリゴヌクレオチド調節
JP2003503048A (ja) Ｓｈｉｐ−２発現のアンチセンスモジュレーション
WO2000017223A1 (en) ANTISENSE MODULATION OF RhoA EXPRESSION
EP1082456A1 (en) Antisense modulation of cd40 expression
AU765928B2 (en) Antisense modulation of transforming growth factor-beta expression
US6440738B1 (en) Antisense modulation of casein kinase 2-beta expression
US5958771A (en) Antisense modulation of cellular inhibitor of Apoptosis-2 expression
KR100622275B1 (ko) 인슐린 유사 성장 인자 결합 단백질 5 발현의 안티센스 조절
US6228648B1 (en) Antisense modulation of ADAM10 expression
JP2002531469A (ja) アポトーシス−１の細胞性阻害物質の発現のアンチセンスモジュレーション
US20020004490A1 (en) Antisense modulation of Fas mediated signaling
US20040023908A1 (en) Antisense modulation of a20 expression
JP2003505037A (ja) テロメアリピート結合因子１発現のアンチセンスモジュレーション
US20030144225A1 (en) Antisense modulation of macrophage inflammatory protein 3-alpha expression
HK1153748A (en) Antisense modulation of c-reactive protein expression